ChlVPP is better than PABIOE for treating advanced Hodgkin's disease
Author Information
Author(s): Hancock B W, Gregory W M, Cullen M H, Hudson G Vaughan, Burton A, Selby P, Maclennan K A, Jack A, Bessell E M, Smith P, Linch D C
Primary Institution: YCR Section of Clinical Oncology, Weston Park Hospital
Hypothesis
Is ChlVPP alternating with PABIOE more effective than PABIOE alone in treating advanced Hodgkin's disease?
Conclusion
ChlVPP alternating with PABIOE is more effective than PABIOE alone for initial treatment of advanced Hodgkin's disease.
Supporting Evidence
- The complete remission rates were 78% for ChlVPP/PABlOE and 64% for PABIOE after initial chemotherapy.
- After radiotherapy, the complete remission rates improved to 88% for ChlVPP/PABlOE and 77% for PABIOE.
- The treatment associated mortality was 2.2% in the PABIOE arm, with no deaths in the ChlVPP/PABlOE arm.
- Failure-free survival was significantly greater in the ChlVPP/PABlOE arm.
- Overall survival rates at 3 years were 91% for ChlVPP/PABlOE compared to 85% for PABIOE.
Takeaway
Doctors found that a new combination of medicines works better than an older one for treating a type of cancer called Hodgkin's disease.
Methodology
A randomized controlled trial comparing two chemotherapy regimens in patients with advanced Hodgkin's disease.
Limitations
41 patients were excluded from analysis due to not meeting protocol requirements.
Participant Demographics
Patients with advanced Hodgkin's disease, aged and gender not specified.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website